Indian Pharma industry moving towards formulations

Indian Pharma industry is slowing moving up the value chain. Earlier it used to manufacture active pharmaceutical ingredient at low cost compared to world. Now with competition from China, which provides API at 15-20% low cost, it makes sense to shift focus elsewhere. Many top companies like Lupin, Novartis, Ranbaxy have less revenue stream from API than from formulations. There could also be the reason that formulation business has grown faster than APIs for some companies. API is low scale commodity with low margin. Moreover, with a large number of patent expiries in developed markets like the US and Europe, Indian companies, with skills to develop and manufacture low-cost generic drugs, see a much more lucrative opportunity there than utilising their capacities for manufacturing APIs.
Read More

  • No Image
    Nright Nutrition Pvt Ltd

    Nright Nutrition Pvt Ltd is incubated by Ram-Nath & Co. Pvt. Ltd, a seven decade organization engaged in the supply of bulk chemicals and polymers. They are engaged in product

  • No Image
    Nutraplus Product India Ltd

    Nutraplus India has started commercial production of anti-malarial drug Lumefantrine at its new plant at Tarapur in Maharashtra. Earlier, the company has been manufacturing int

  • No Image
    Ocean Healthcare Pvt Ltd

    Ocean Healthcare Pvt Ltd incorporated in 2013 was promoted by Mr Siddharth Baid, Mr Venkateesh Veera, Medinomics Healthcare Private Limited and Hayat Pharmaceutical Industries